Optimal low-density lipoprotein cholesterol lowering—morning versus evening statin administration
R Plakogiannis, H Cohen - Annals of Pharmacotherapy, 2007 - journals.sagepub.com
Objective: To determine the best time to administer statins for optimal lowering of low-density
lipoprotein cholesterol (LDL-C) by reviewing the clinical evidence evaluating the …
lipoprotein cholesterol (LDL-C) by reviewing the clinical evidence evaluating the …
Chronotherapy versus conventional statins therapy for the treatment of hyperlipidaemia
JM Izquierdo‐Palomares… - Cochrane Database …, 2016 - cochranelibrary.com
Background Elevated levels of total cholesterol and low‐density lipoprotein play an
important role in the development of atheromas and, therefore, in cardiovascular diseases …
important role in the development of atheromas and, therefore, in cardiovascular diseases …
Use of atorvastatin in lipid disorders and cardiovascular disease in Chinese patients
YC Ye, XL Zhao, SY Zhang - Chinese Medical Journal, 2015 - mednexus.org
Objective: Statins are still underused for the prevention of cardiovascular disease (CVD) in
China. Hence, we conducted a systemic review on the pharmacology, clinical efficacy, and …
China. Hence, we conducted a systemic review on the pharmacology, clinical efficacy, and …
Atorvastatin induces apoptosis by a caspase‐9‐dependent pathway: an in vitro study on activated rat hepatic stellate cells
I Aprigliano, J Dudas, G Ramadori, B Saile - Liver international, 2008 - Wiley Online Library
Background: Statins are shown to have cholesterol‐independent properties such as anti‐
inflammation and immunomodulation. Activated hepatic stellate cells (HSCs) acquire the …
inflammation and immunomodulation. Activated hepatic stellate cells (HSCs) acquire the …
Rosuvastatin and atorvastatin: comparative effects on glucose metabolism in non-diabetic patients with dyslipidaemia
A Abbas, J Milles… - Clinical Medicine Insights …, 2012 - journals.sagepub.com
The ever increasing interventional CVD outcome studies have resulted in statins being an
essential factor of cardiovascular prevention strategies. The JUPITER study in 2008, despite …
essential factor of cardiovascular prevention strategies. The JUPITER study in 2008, despite …
Atorvastatin Calcium: An Addition to HMG‐CoA Reductase Inhibitors
PH Chong, JD Seeger - Pharmacotherapy: The Journal of …, 1997 - Wiley Online Library
Atorvastatin calcium is an HMG‐coenzyme A (CoA) reductase inhibitor that was approved by
the Food and Drug Administration on December 17, 1996. Like other such agents, it inhibits …
the Food and Drug Administration on December 17, 1996. Like other such agents, it inhibits …
Doravirine: a new non-nucleoside reverse transcriptase inhibitor for the treatment of HIV infection.
R Talwani, Z Temesgen - Drugs of today (Barcelona, Spain: 1998), 2020 - europepmc.org
Doravirine is a new non-nucleoside reverse transcriptase inhibitor (NNRTI) that was
approved by the United States Food and Drug Administration (FDA) on August 30, 2018, for …
approved by the United States Food and Drug Administration (FDA) on August 30, 2018, for …
Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias
HS Yee, NT Fong - Annals of Pharmacotherapy, 1998 - journals.sagepub.com
OBJECTIVE: To review the efficacy and safety of atorvastatin in the treatment of
dyslipidemias. DATA SOURCES: A MEDLINE search (January 1960–April 1998), Current …
dyslipidemias. DATA SOURCES: A MEDLINE search (January 1960–April 1998), Current …
[HTML][HTML] Reduction of high cholesterol levels by a preferably fixed-combination strategy as the first step in the treatment of hypertensive patients with …
G Grassi, R Del Pinto, C Agabiti Rosei… - High Blood Pressure & …, 2022 - Springer
The primary and secondary prevention strategies of atherosclerotic cardiovascular disease
(ASCVD) largely rely on the management of arterial hypertension and …
(ASCVD) largely rely on the management of arterial hypertension and …
Atorvastatin
SI van Leuven, JJP Kastelein - Expert opinion on pharmacotherapy, 2005 - Taylor & Francis
The introduction of statins has drastically changed the treatment and prevention of
atherosclerotic vascular disease. By lowering lipid levels and reducing the risk of coronary …
atherosclerotic vascular disease. By lowering lipid levels and reducing the risk of coronary …